We thank the authors of all 4 letters to the editor1–4 for their interest in our randomized controlled trial on surveillance using abdominal ultrasound (US) alone vs US with serum biomarkers (BMs) for detection of early-stage hepatocellular carcinoma (HCC).5 Herein, we provide a consolidated response addressing overarching points and specific issues where appropriate.
We will be happy to hear your thoughts